NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its primary endpoint, achieving a statistically significant reduction in liver fat content, robust fibrosis improvement, and resolution of NASH, with a favorable safety profile.

For detailed information, see the below URL.

https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-presents-comprehensive-findings-24-week-phase-2-study

It has been reported that administration of Aldafermin, an analog of FGF19, improves NASH and fatty liver-derived fibrosis.
The results are likely to further accelerate planning for Aldafermin's Phase 3 trial.